Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD

European Respiratory Journal

Volumn 11, Issue 6, 1998, Pages 1337-1341

  Cazzola, M ^a,c   Di Perna, F ^a,b   Noschese, P ^a   Vinciguerra, A ^a   Calderaro, F ^a,b   Girbino, G ^b   Matera, M G ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c NONE   (Italy)

Author keywords

Chronic obstructive pulmonary; Disease; Formoterol; Oxitropium bromide; Salbutamol; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL; LONG ACTING DRUG; OXITROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL;

ADULT; AIRWAY DYNAMICS; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; BRONCHI; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PARASYMPATHOLYTICS; SCOPOLAMINE DERIVATIVES; SPIROMETRY; VITAL CAPACITY;

EID: 0031835803     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.11061337     Document Type: Article

References (30)

1. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814-819.
2. Postma DS, de Vries K, Koeter GH, Sluiter HJ. Independent influence of reversibility of airflow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 1986; 134: 276-280.
3. Chapman KR, Bowie OM, Goldstein RS, et al. Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group. Can Med Ass J 1992; 147: 420-428
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S72-S120.
5. 2-agonist, in chronic obstructive airway disease. Lung 1990; 168 (Suppl.): 83-89.
6. Di Lorenzo G, Barbagallo Sangiorgi G, Ravinetto R, Squassante L, Zanferrari G. Inhaled salmeterol and oral theophylline in patients with chronic bronchitis: a multicentre clinical comparison. Giorn It Med Torac 1995; Suppl. 53.
7. Jaeschke R, Guyatt GH, Cook O, et al. The effect of increasing doses of β-agonists on airflow in patients with chronic airflow limitation. Respir Med 1993; 87: 433-438.
8. Newhouse N, Dolovich M. Aerosol therapy: nebulized vs metered dose inhaler. Chest 1987; 91: 799-800.
9. Lipworth BJ, Grove A. Evaluation of partial β-adrenoceptor agonist activity. Br J Clin Pharmacol 1997; 43: 9-14.
10. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis 1987; 136: 1285-1298.
11. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42: 487-490.
12. 2-adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995; 50: 134-138.
13. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.
14. Wagner J, Reinhardt D, Schumann HJ. Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, terbutaline and salbutamol in cats and isolated organ preparations. Res Exp Med 1974; 162: 49-62.
15. Lindén A, Bergendal A, Ullman A, Skoogh B-E, Löfdahl C-G. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993; 48: 547-553.
16. Smyth ET, Pavord ID, Wong CS, Wisniewski AFZ, Williams J, Tattersfield AK. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. Br Med J 1993; 306: 543-545.
17. 2-adrenoceptor agonist salmeterol in guinea-pig trachea. Br J Pharmacol 1991; 104: 1057-1061.
18. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 1994; 7: 914-920.
19. 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol 1994; 113: 687-692.
20. 2-adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996; 51: 54-58.
21. 2 responses to fenoterol. Thorax 1996; 51: 585-589.
22. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.
23. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105: 1411-1419.
24. Imhof E, Elasser S, Karrer W, et al. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration 1993; 60: 84-88.
25. Koyama H, Nishimura K, Ikeda A, Izumi T. A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease. Chest 1993; 104: 1743-1747.
26. Nishi K, Fujimura K, Myou S, et al. Comparison of the bronchodilator activities of oxitropium bromide, fenoterol, and their combination in patients with chronic obstructive pulmonary disease and bronchial asthma. Clin Auton Res 1993; 3: 41-44.
27. 2-adrenoceptors. J Appl Physiol 1988; 65: 700-705.
28. Newnham DM, Dhillon DP, Winter JH, et al. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax 1993; 48: 1151-1155.
29. Sobol BJ. Some problems encountered in the evaluation of bronchodilator therapy. Chest 1978; 73 (Suppl.): 991-992.
30. Barclay J, Whiting B, Addis GJ. The influence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1982; 22: 389-393.